Merck rose nearly 7% as its new antithrombotic drug is expected to be approved by FDA
-
Last Update: 2014-01-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The stock price of us pharmaceutical giant Merck (NYSE: MRK) rose nearly 7% on Monday, hitting a new high since its IPO Its antithrombotic drug, vorapaxar, is expected to get FDA approval, boosting its share price The food and Drug Administration will review vorapaxar on Wednesday As the results of the clinical trials of vorapaxar are satisfactory, it is highly likely that FDA will finally approve its marketing Vorapaxar is designed to prevent heart attacks and strokes Boosted by the positive news, Merck pharmaceutical shares rose 6.46% to close at $53.10 The share price rose to $53.44, a new high since its IPO At Monday's closing price, it has a market value of $160.302 billion Merck has invested $8 billion in research and development of vorapaxar, and hopes that vorapaxar will be licensed to prevent recurrence in patients with first-time heart disease It has been very difficult to approve heart disease drugs Tredaptive, another new cardiovascular drug of Merck, has been denied by FDA.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
